THAR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
THAR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tharimmune's EBITDA per Share for the three months ended in Sep. 2024 was $-2.45.
During the past 3 years, the average EBITDA Per Share Growth Rate was -13.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Tharimmune was -13.90% per year. The lowest was -68.10% per year. And the median was -41.00% per year.
For the Biotechnology subindustry, Tharimmune's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Tharimmune's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Tharimmune's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Tharimmune (NAS:THAR) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Thank you for viewing the detailed overview of Tharimmune's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Sireesh Appajosyula | director | 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807 |
Randy Milby | director, officer: Chief Executive Officer | 5 JACK LANE, NEWARK DE 19711 |
Kelly Anderson | director | C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212 |
Leonard L Mazur | director | C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016 |
Sandeep Laumas | 10 percent owner | 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
Thomas Hess | officer: Chief Financial Officer | 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017 |
Lynne A. Bui | director | 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807 |
Surender Kharbanda | 10 percent owner | 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807 |
Highpoint Pharmaceuticals Llc | 10 percent owner | 16192 COASTAL HIGHWAY, LEWES DE 19958 |
Kufe Llc | 10 percent owner | 179 GROVE STREET, WELLESLEY MA 02482 |
Varinder Kaur | 10 percent owner | 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807 |
From GuruFocus
By ACCESSWIRE • 06-11-2024
By ACCESSWIRE • 07-16-2024
By ACCESSWIRE • 04-23-2024
By ACCESSWIRE • 05-29-2024
By ACCESSWIRE • 10-25-2024
By GuruFocus Research • 02-09-2024
By ACCESSWIRE • 09-30-2024
By ACCESSWIRE • 11-13-2024
By ACCESSWIRE • 05-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.